Contact Dermatitis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Contact Dermatitis – Drugs In Development, 2022, provides an overview of the Contact Dermatitis (Dermatology) pipeline landscape.
Contact dermatitis is a type of skin inflammation that occurs when substances touching skin cause irritation or an allergic reaction. Signs and symptoms of contact dermatitis include red rash or bumps, dry, cracked, red patches, which may resemble a burn and pain or tenderness. There are two types of contact dermatitis; irritant and allergic. Irritant dermatitis, the most common type, is caused by contact with acids, alkaline materials such as soaps and detergents, fabric softeners, solvents, or other chemicals. The reaction usually looks like a burn. Allergic contact dermatitis is an itchy skin condition caused by an allergic reaction to allergen. Treatment includes oral corticosteroids and antihistamines to relieve intense itching.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Contact Dermatitis – Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Contact Dermatitis (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Contact Dermatitis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Contact Dermatitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 4 and 1 respectively. Similarly, the Universities portfolio in Phase III stages comprises 1 molecules, respectively.
Contact Dermatitis (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook